Nov. 15, 2023 Price forecast | 2 weeks: -2.51% | 1 month: -4.24% | 3 months: -8.12%


TCON stock forecast

Our latest prediction for TRACON Pharmaceuticals Inc's stock price was made on the Nov. 15, 2023 when the stock price was at 0.17$.

In the short term (2weeks), TCON's stock price should underperform the market by -2.51%. During that period the price should oscillate between -13.01% and +9.73%.

In the medium term (3months), TCON's stock price should underperform the market by -8.12%. During that period the price should oscillate between -31.84% and +17.89%.

Create a solid portfolio with TCON

Add TCON to your portfolio and optimize it!


About TRACON Pharmaceuticals Inc

tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w

At the moment the company generates 20M USD in revenues.

On its last earning announcement, the company reported a loss of -0.57$ per share.

The book value per share is 1.24$

TRACON Pharmaceuticals Inc website


Three months stock forecastNov. 15, 2023


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
20M - -15M - -2M -0.57 - - 31M 1.24 - - -